CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastati...(ward to furtherevaluating the correlatio...),Health

CuraGen is currently enrolling patients into a Phase I portion of this trial to evaluate more frequent dosing schedules of CR011-vcMMAE, including a weekly and a two out of every three-week regimen, to explore if more frequent administration can provide additional activity in patients with metastatic melanoma. CR011-vcMMAE is also being studied in an ongoing Phase II trial in patients with metastatic breast cancer who have received previous chemotherapy. CuraGen anticipates providing updated data from the ongoing melanoma and breast cancer studies in the first half of 2009.

"While we continue to finalize data from this study, develop data from more frequent dosing in patients with metastatic melanoma and from the Phase II study in patients with breast cancer, we will be engaging in discussions with potential partners as we develop plans for the advanced stages of development," added Dr. Shannon. "The goal of a partnership will be to support the financial, development and commercial resources that will be required in advanced development, improving the risk profile to CuraGen shareholders while maintaining upside potential."

In addition to M. D. Anderson, other sites participating in the melanoma trial include Yale Cancer Center, New Haven, CT; The Angeles Clinic and Research Institute, Santa Monica, CA; and New York University Medical Center, New York, NY.

Reprints of the presentation will be made available on CuraGen's website at http://www.curagen.com or can be requested by emailing info@curagen.com.

Conference Call Details and Dial-in Information

Date: Monday, November 3, 2008

Time: 11:00 a.m. EDT

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 71190
'/>"/>